Neurocrine Biosciences Says Kevin Gorman Will Retire As CEO On October 11, 2024; Kyle Gano Named As Successor
Kyle Gano, Ph.D., currently Neurocrine's Chief Business Development and Strategy Officer, will succeed him in the CEO role. Gano will also join the Company's Board of Directors at that time, and Gorman will continue to serve on the Neurocrine Board.